Kala Bio, Inc. Files 8-K on Executive Changes and Restructuring
Ticker: KALA · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1479419
Sentiment: neutral
Topics: executive-changes, restructuring, board-changes, officer-appointments
Related Tickers: KALA
TL;DR
KALA's making executive moves and restructuring - watch for updates.
AI Summary
Kala Bio, Inc. filed an 8-K on October 20, 2025, reporting on several events. These include cost associated with exit or disposal activities, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing also covers other events.
Why It Matters
This filing indicates potential organizational changes and restructuring within Kala Bio, Inc., which could impact its strategic direction and operational focus.
Risk Assessment
Risk Level: medium — The filing details changes in directors and officers, and costs associated with exit or disposal activities, suggesting potential strategic shifts or challenges within the company.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- 001-38150 (company) — Commission File Number
- 27-0604595 (company) — IRS Employer Identification No.
- 1167 Massachusetts Avenue (company) — Principal Executive Offices Address
- Arlington, MA 02476 (company) — Principal Executive Offices Location
- October 19, 2025 (date) — Date of earliest event reported
- October 20, 2025 (date) — Date of Report
FAQ
What specific costs are associated with the exit or disposal activities mentioned in the filing?
The filing does not specify the exact dollar amounts for costs associated with exit or disposal activities, but lists it as an item of information.
Who are the directors or officers that have departed from Kala Bio, Inc.?
The filing indicates the departure of directors or certain officers as an item of information but does not name the individuals involved.
Were there any new directors or officers elected or appointed on or around October 19, 2025?
The filing lists the election of directors and appointment of certain officers as items of information, but does not provide specific names or details of these appointments.
What are the details of the compensatory arrangements for certain officers?
The filing notes compensatory arrangements of certain officers as an item of information but does not provide specific details of these arrangements.
What is the nature of the 'Other Events' reported by Kala Bio, Inc.?
The filing lists 'Other Events' as an item of information but does not provide any specific details regarding these events.
Filing Stats: 1,234 words · 5 min read · ~4 pages · Grade level 14.2 · Accepted 2025-10-20 08:00:18
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq
- $9.6 million — ford continues to be owed approximately $9.6 million by the Company. Unless Oxford's foreclo
Filing Documents
- kala-20251019x8k.htm (8-K) — 35KB
- 0001104659-25-100620.txt ( ) — 141KB
- kala-20251019.xsd (EX-101.SCH) — 3KB
- kala-20251019_lab.xml (EX-101.LAB) — 15KB
- kala-20251019_pre.xml (EX-101.PRE) — 9KB
- kala-20251019x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events As described above, on October 18, 2025, pursuant to the terms of the Loan Agreement, Oxford informed the Company that it intended to foreclose on all of the Company's remaining assets and that Oxford would not consent to the Company's use of cash for any reason other than for minimal payroll expenses pending Oxford's foreclosure of the Company's assets. In addition, Oxford has swept substantially all of the Company's cash resources from its bank accounts. After applying the swept cash to its secured debt claims, Oxford continues to be owed approximately $9.6 million by the Company. Unless Oxford's foreclosure on the Company's noncash assets results in proceeds in excess of the amount of Oxford's remaining claim, the Company does not believe that any distributions to stockholders or unsecured creditors will be available following Oxford's foreclosure and in connection with any dissolution of the Company. In addition, given Oxford's control of the Company's cash resources and Oxford's limitation on the use of the Company's cash resources, the Company does not expect to be able to continue to file reports with Securities and Exchange Commission, including but limited to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 and the Annual Report on Form 10-K for the fiscal year ending December 31, 2025. The Company also expects that its common stock will be delisted from The Nasdaq Capital Market. Cautionary Note Regarding Forward Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: October 20, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary